Skip to main content
. 2021 Dec 6;5(23):5128–5139. doi: 10.1182/bloodadvances.2021005220

Figure 3.

Figure 3.

PFS-B and PFS-AB stratified according to best response to daratumumab monotherapy. (A) PFS-B and (B) PFS-AB stratified according to best response to daratumumab monotherapy during part A of the study (PR or better, SD/MR, or PD). NE, not evaluable.